Clinical Trial Begins for Prion Disease Drug Candidate Targeting Prion Protein

First Human Trial for Prion Disease siRNA

A phase 1 clinical trial has commenced for a drug candidate aimed at treating prion disease. This marks the first time a small interfering RNA (siRNA) targeting the prion protein is being tested in humans. The trial will evaluate the safety and tolerability of the potential medicine.

Mechanism of Action

The drug candidate is a divalent siRNA molecule developed by scientists at the Broad Institute and the University of Massachusetts Chan Medical School. It is designed to bind and cleave RNA molecules that encode the prion protein, thereby reducing the amount of the disease-causing protein in the brain. Previous animal studies indicated that lowering prion protein levels could delay disease onset and slow its progression.

Trial Details and Objectives

The trial, named PrP-targeting siRNA Safety & Mechanism Study (PRiSM), will enroll 15 patients diagnosed with prion disease who are already exhibiting symptoms of the neurodegenerative disorder. The primary objectives are to test the safety and appropriate dosing of the siRNA, which will inform decisions on whether to advance the drug candidate to larger clinical trials.

Addressing an Unmet Medical Need

Prion diseases are fatal neurodegenerative disorders caused by the accumulation of misfolded prion protein in the brain. Currently, there are no cures, and patients typically succumb to the disease within months or years after symptom onset. This trial represents a step towards developing a treatment for this condition.